Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Washington
Study ID
NCT05822609
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Key Dates

Start date
Apr 5, 2024
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Semaglutide group from 0.25mg to 1.0mg
  • Placebo Comparator: Placebo
    Placebo group

Primary Outcome Measure

Change in urine albumin excretion [ Time Frame: Baseline to 26 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of Colorado Anschutz Medical CampusAuroraColorado80045
Madeline Harbour, BA
720-689-4751
Carissa Birznieks, BS
720-689-4751
Jessica Kendrick, MD (PRINCIPAL_INVESTIGATOR)
University of WashingtonSeattleWashington98104
Jesica D Baran
425-624-7899
Dori Khakpour, RDN CDE
206-945-4954
Irl Hirsch, MD (PRINCIPAL_INVESTIGATOR)
Providence Sacred Heart Medical CenterSpokaneWashington99204
Nicole Maser, MSN RN
509-474-5313
Susan Hood, PhD CCRC
509-474-4224
Katherine Tuttle, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Aurora, CO

By condition
By specialty

Related Studies